AUTHORS
Keyvan Karkouti, MD, Jeannie Callum, MD, FRCPC2, Justyna Bartoszko3, Michelle Zeller, MD, MSc, FRCPC4, Yulia Lin, MD5, Darren Mullane6, Cristina Solomon, MD, MBA7, Sigurd Knaub, PhD8, Sylvia Werner, MSc9, Kenichi A Tanaka10, Jerrold H Levy, MD11
AFFILIATIONS
1 University Health Network, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
2 Kingston Health Sciences Centre, Kingston, Ontario, Canada, Queen's University, Kingston, Ontario, Canada
3 University Health Network, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
4 Canadian Blood Services, Ottawa, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
5 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
6 University of British Columbia, Vancouver, British Columbia, Canada, Vancouver General Hospital, Vancouver, British Columbia, Canada
7 Octapharma AG, Lachen, Switzerland
8 Octapharma AG, Lachen, Switzerland
9 Octapharma USA, Inc., Paramus, New Jersey, United States
10 University of Oklahoma-Health Sciences Center, Oklahoma City, Oklahoma, United States
11 Duke University School of Medicine, Durham, North Carolina, United States, University of British Columbia, Vancouver, British Columbia, Canada
ABSTRACT
Introduction:
The FARES-II randomized, active-control, Phase 3, pragmatic study showed that four-factor prothrombin complex concentrate (4F-PCC; Octaplex/BALFAXAR, Octapharma) was clinically superior to frozen plasma (FP) for hemostatic effectiveness, without increasing thromboembolic risk, in cardiac surgery patients requiring coagulation factor replacement (currently off-label in the US) [Karkouti et al JAMA 2025;333:1781–92]. Furthermore, serious adverse events and acute kidney injury were significantly less frequent with 4F-PCC. To further characterize the role of 4F-PCC in these patients, we performed prespecified subgroup analyses of the primary and secondary study outcomes stratified by sex.
Methods:
FARES-II (LEX-211; NCT05523297) was conducted at 12 hospitals in Canada and the US in accordance with the Declaration of Helsinki. Patients were ≥18 years, underwent cardiac surgery with cardiopulmonary bypass (CPB), required coagulation factor replacement due to bleeding and known (e.g., elevated international normalized ratio [INR]) or suspected coagulation factor deficiency, and received PCC (1500 IU if ≤60 kg; 2000 IU if >60 kg) or FP (3 U if ≤60 kg; 4 U if >60 kg) in the operating room (maximum 2 doses within 24 h; FP used thereafter). Clinical teams were blinded to group allocation until treatment start. Transfusion of other blood products and hemostatic agents was per local standard-of-care practice. INR and hemoglobin were measured at pre-established time points. No other aspects of routine clinical care were modified.
The primary endpoint was hemostatic response (effective if no additional hemostatic interventions were administered from 60 min to 24 h after treatment initiation). Secondary endpoints included bleeding, allogeneic blood product (ABP) transfusions, use of other coagulation factor products, INR, other standard laboratory coagulation tests, and point-of-care viscoelastic coagulation tests. Safety endpoints included 30-day treatment-emergent thromboembolic events (TEEs) and death.
Results:
Of 538 enrolled patients, 420 were randomized, treated, consented, and included in the analysis (4F-PCC=213; FP=207). Baseline characteristics were comparable between groups. Overall, the median age was 66 (interquartile range, 57–73) years and 296 (70.5%) patients had undergone complex operations. In the primary analysis set, 56 (26.3%) patients in the 4F-PCC group and 55 (26.6%) patients in the FP group were female.
For both female and male patients, 4F-PCC was non-inferior, and superior, to FP for the primary endpoint. In female patients, hemostatic response was effective in 47 (83.9%) patients in the 4F-PCC group vs. 32 (58.2%) patients in the FP group (estimated difference 25.75; 95% CI 8.73, 42.76; p<0.0001). In male patients, hemostatic response was effective in 119 (75.8%) patients in the 4F-PCC group vs. 93 (61.2%) patients in the FP group (estimated difference 14.61; 95% CI 4.25, 24.98; p<0.0001).
Chest tube drainage at 12 h after chest closure was lower in the 4F-PCC group vs. the FP group for both females (least-squares mean, −227.25 mL; p=0.0036) and males (−150.84 mL; p=0.0016), as was the incidence of severe to massive bleeding within 24 h after study drug initiation (8.9% vs. 32.7%, p=0.0036 in females; 15.9% vs. 34.9%, p=0.0002 in males). The mean number of ABP units transfused within 24 h after study drug initiation, excluding intervention FP, was statistically significantly lower with 4F-PCC vs. FP for females (2.5 vs. 8.5; p<0.0001) and numerically lower for males (4.7 vs. 6.1; p=0.15). The mean reduction in INR post-treatment was statistically significantly greater with 4F-PCC vs. FP for males (−0.13; p=0.002) and numerically greater for females (−0.21; p=0.23).
Conclusions:
The FARES-II randomized trial demonstrated that, in both female and male patients, 4F-PCC was more efficacious than FP in controlling post-CPB coagulopathic bleeding. When the primary and secondary endpoints were examined by sex, the hemostatic benefit of 4F-PCC was numerically greater in females than in males. Whether this apparent difference reflects a true sex-specific treatment effect and, if so, whether it is related to differences in body weight and circulating volume, dose of 4F-PCC per kg body weight, or other factors, warrants further investigation.
DISCLOSURES
Cristina Solomon, MD, MBA: Octapharma - Current Employment